Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50.7 PLN | +2.42% | +4.32% | -11.83% |
Sales 2024 * | 152M 38.04M | Sales 2025 * | 218M 54.5M | Capitalization | 1.17B 294M |
---|---|---|---|---|---|
Net income 2024 * | -161M -40.34M | Net income 2025 * | -119M -29.81M | EV / Sales 2024 * | 7.24 x |
Net cash position 2024 * | 73.62M 18.45M | Net Debt 2025 * | 18.41M 4.61M | EV / Sales 2025 * | 5.47 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | +2.42% | ||
1 week | +4.32% | ||
Current month | +2.42% | ||
1 month | -7.31% | ||
3 months | -15.36% | ||
6 months | -8.32% | ||
Current year | -11.83% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 50.7 | +2.42% | 4,140 |
24-05-09 | 49.5 | -0.70% | 2,192 |
24-05-08 | 49.85 | -2.25% | 2,291 |
24-05-07 | 51 | -1.54% | 1,786 |
24-05-06 | 51.8 | +6.58% | 5,235 |
Delayed Quote Warsaw S.E., May 10, 2024 at 11:55 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.83% | 294M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- RVU Stock